PATIENT
ENROLLMENT FORMS
Review the patient enrollment process and download the necessary forms.
Review the patient enrollment process and download the necessary forms.
Get information on prognostic evaluation and risk assessment for your patients with PAH by using the 2015 ESC/ERS Guidelines for every office visit.2
ERS=European Respiratory Society
ESC=European Society of Cardiology
With the Aim Patient Support Program, your Adempas patients are covered every step of the way. Here, you can find all of the resources for your patients on their journey. The Aim Patient Support Program is comprised of 3 components: myAim Education and Encouragement, nursing support, and access and financial support.
Throughout treatment, it is important that your PAH and CTEPH patients know they are not alone and can connect with people who are living with their conditions. Read about different patient experiences and become more aware about the struggles of their everyday lives and how Adempas can help.
Adempas® (riociguat) is a soluble guanylate cyclase (sGC) stimulator, the first member of a distinct class of compounds, discovered and developed by Bayer as an oral treatment to target a key molecular mechanism underlying pulmonary hypertension (PH).1,2
inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
persistent or recurrent CTEPH after surgery to improve exercise capacity
pulmonary arterial hypertension (PAH with WHO functional class II to III, to improve exercise capacity), idiopathic or PAH associated with connective tissue diseases.1-3
PH is a severe, progressive, and life-threatening disorder of the lungs and heart characterized by elevated blood pressure in the pulmonary arteries, which can lead to right heart failure and death if left untreated.6,7 There are five types of PH; each can affect the patient in a different way and every patient may have a different etiology of PH.8-10
Adempas® has a dual mode of action – directly stimulating sGC independently of endogenous nitric oxide (NO) and also facilitating the binding of any remaining endogenous NO to sGC .1,2,15 Patients with CTEPH and PAH are often nitric oxide deficient; this results in sGC being under-stimulated and is associated with a poor prognosis.16-18 For patients with CTEPH and PAH, sGC stimulation is fundamental for providing treatment success and helping to regulate vascular tone, proliferation and inflammation.16-18
Disclaimer: Please refer to your country’s specific Adempas® label and prescribing information, as they can differ from the Adempas® Expanded Company Core Data Sheet used to reference this global website.